The Apolipoprotein B pipeline drugs market research report outlays comprehensive information on the Apolipoprotein B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Apolipoprotein B pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Immunology, Metabolic Disorders, and Central Nervous System which include the indications Acute Coronary Syndrome, Atherosclerosis, Rheumatoid Arthritis, Inflammation, Homozygous Familial Hypercholesterolemia (HoFH), Heterozygous familial hypercholesterolemia (heFH), and Multiple Sclerosis. It also reviews key players involved in Apolipoprotein B targeted therapeutics development with respective active and dormant or discontinued products.
The Apolipoprotein B pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 2, and 1 respectively.
Apolipoprotein B overview
Apolipoprotein B (ApoB) is a protein that plays a key role in lipid metabolism, particularly in the transport of lipids (fats) through the bloodstream. There are two major forms of ApoB: ApoB-100 and ApoB-48. ApoB-100 form is primarily associated with low-density lipoprotein (LDL) particles, which are commonly referred to as “bad cholesterol.” ApoB-100 is synthesized in the liver and is an essential component of LDL particles, which transport cholesterol and other lipids from the liver to peripheral tissues. ApoB-48 form is found in chylomicrons, which are lipoprotein particles formed in the small intestine. ApoB-48 is synthesized when dietary fats are absorbed in the intestines. Chylomicrons transport dietary triglycerides and other lipids from the intestines to various tissues. ApoB is a large glycoprotein with a molecular weight of around 500 kDa. ApoB-100 is significantly larger than ApoB-48. ApoB is synthesized in the liver for ApoB-100 and in the small intestine for ApoB-48. The synthesis of ApoB is tightly regulated and is influenced by dietary and hormonal factors. Measurement of ApoB levels is used in clinical settings as a marker for assessing cardiovascular risk.
For a complete picture of Apolipoprotein B’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
